Company overview
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing INMB with another company.
| Daily close (USD) | $1.83 |
| Market capitalization (USD) | $50,789,433.87 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.49 |
No matching rows. Clear the filter to see all records.
Read INMB's valuation metrics
Company size
INmune Bio Inc. Common stock's recorded market capitalization is $50,789,433.87. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
INMB's recorded price-to-book ratio is 2.49. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research INmune Bio Inc. Common stock with Aurora
Use the snapshot above to ask a specific question about INMB. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow INMB's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.